Ranolazine in Atrial Fibrillation Following An ELectricaL CardiOversion
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
Dose-ranging Phase II study testing the efficacy and safety of 3 doses of Ranolazine (low,
intermediate and high, given BID) versus placebo in maintaining sinus rhythm after successful
electrical cardioversion in patients with persistent atrial fibrillation (AFib).
After successful cardioversion and subsequent randomisation, patients report trans-telephonic
EGCs on a daily basis to a central core ECG facility.
Maximum treatment duration is 112 days (16 weeks).